Audeo Oncology (Audeo Oncology) COGS-to-Revenue : 0.00 (As of Sep. 2012)

View and export this data going back to . Start your Free Trial

What is Audeo Oncology COGS-to-Revenue?

Audeo Oncology's Cost of Goods Sold for the three months ended in Sep. 2012 was $0.00 Mil. Its Revenue for the three months ended in Sep. 2012 was $0.06 Mil.

Audeo Oncology's COGS to Revenue for the three months ended in Sep. 2012 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Audeo Oncology's Gross Margin % for the three months ended in Sep. 2012 was N/A%.

Audeo Oncology COGS-to-Revenue Historical Data

The historical data trend for Audeo Oncology's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Audeo Oncology COGS-to-Revenue Chart

Audeo Oncology Annual Data

Trend

Jun10

Jun11

Jun12

COGS-to-Revenue

Audeo Oncology Quarterly Data
	Jun11	Mar12	Jun12	Sep12
COGS-to-Revenue	-	-	-	-

Audeo Oncology COGS-to-Revenue Calculation

Audeo Oncology's COGS to Revenue for the fiscal year that ended in Jun. 2012 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Audeo Oncology's COGS to Revenue for the quarter that ended in Sep. 2012 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0.061
	=	0.00

Audeo Oncology (DELISTED:AURX) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Audeo Oncology's Gross Margin % for the three months ended in Sep. 2012 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0.061
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Audeo Oncology COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Audeo Oncology's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Audeo Oncology (Audeo Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Audeo Oncology Inc (DELISTED:AURX) » Definitions » COGS-to-Revenue

Traded in Other Exchanges

N/A

Address

Website

http://www.audeooncology.com

Audeo Oncology, Inc was incorporated in Delaware in June 2012. It is a late stage biopharmaceutical company utilizing its Hyaluronic Acid Chemotransport Technology, or HyACT, to target cancer drugs preferentially to tumor cells to enhance drug activity. HyACT is a flexible platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. It seeks to reduce the risks related to drug development by using known anti-cancer drugs, and aim to enhance their commercial value by improving their effectiveness. The Company's lead HyACT product candidate, HA-Irinotecan, is currently in a pivotal Phase III clinical trial for metastatic colorectal cancer, or mCRC. HA-Irinotecan is also in an investigator-sponsored Phase II clinical trial for small cell lung cancer, or SCLC. It also has two other HyACT product candidates that have successfully completed Phase I clinical trials. In addition to its current clinical-stage product candidates, it aims to develop a pipeline of product candidates by exploiting its significant know-how in cancer stem cell biology and cancer metabolism combined with the Versatile Assembly on Stable Templates, or VAST, molecule drug discovery technology that it will in-license. The Company's lead product candidate is HyACT-targeted irinotecan, or HA-Irinotecan, for the treatment of mCRC. Irinotecan, which is marketed in major markets by Pfizer as Camptosar, is an off-patent chemotherapy drug widely used in the treatment of mCRC. Government authorities in the United States (including federal, state and local authorities) and in other countries extensively regulate the manufacture, research, clinical development, labeling, packaging, distribution, post-approval monitoring and reporting, advertising, promotion, export and import of pharmaceutical products, such as those it is developing.